Banu Atalar1, Mahmut Ozsahin2, Jason Call3, Aleksandra Napieralska4, Serra Kamer5, Salvador Villa6, Petek Erpolat7, Laura Negretti2, Yasmin Lassen-Ramshad8, Cem Onal9, Serap Akyurek10, Gamze Ugurluer11, Brigitta G Baumert12, Stephanie Servagi-Vernat13, Robert C Miller14, Enis Ozyar11, Terence T Sio3. 1. Department of Radiation Oncology, Acıbadem University, Istanbul, Turkey. Electronic address: banu.atalar@acibadem.com.tr. 2. Centre Hospitalier Universitaire Vaudois (CHUV), Department of Radiation Oncology, Lausanne, Switzerland. 3. Department of Radiation Oncology, Mayo Clinic Hospital, Phoenix, AZ, United States. 4. Radiotherapy Department, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Poland. 5. Department of Radiation Oncology, Ege University, Izmir, Turkey. 6. Radiation Oncology, Catalan Institute of Oncology, Badalona, Catalonia, Spain. 7. Department of Radiation Oncology, Gazi University, Ankara, Turkey. 8. Oncological Department, Aarhus University Hospital, Denmark. 9. Department of Radiation Oncology, Baskent University, Adana, Turkey. 10. Department of Radiation Oncology, Ankara University, Ankara, Turkey. 11. Department of Radiation Oncology, Acıbadem University, Istanbul, Turkey. 12. Depts. Radiation Oncology (MAASTRO), GROW, Maastricht University MC, Netherlands; Paracelsus Klinik Osnabrueck and University of Muenster, University Bonn MC, Germany. 13. Radiation Oncology, University Hospital of Besancon, France. 14. Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, United States.
Abstract
BACKGROUND AND PURPOSE: The optimal treatment for adults with newly diagnosed medulloblastoma (MB) has not been defined. We report a large series of cases from the Rare Cancer Network. MATERIAL AND METHODS: Thirteen institutions enrolled 206 MB patients who underwent postoperative radiotherapy (RT) between 1976 and 2014. Log-rank univariate and Cox-modeled multivariate analyses were used to analyze data collected. RESULTS: Median patient age was 29 years; follow-up was 31 months. All patients had the tumor resected; surgery was complete in 140 (68%) patients. Postoperative RT was given in 202 (98%) patients, and 94% received craniospinal irradiation (CSI) and, usually, a posterior fossa boost. Ninety-eight (48%) patients had chemotherapy, mostly cisplatin and vincristine-based. The 10-year local control, overall survival, and disease-free survival rates were 46%, 51%, and 38%, respectively. In multivariate analyses, Karnofsky Performance Status (KPS) ≥80 and CSI were significant for disease-free and overall survival (P ≤ .04 for all); receiving chemotherapy and KPS ≥80 correlated with better local-control rates. CONCLUSIONS: Patients with high KPS who received CSI had better rates of disease-free and overall survival. Chemotherapy was associated with better local control. These results may serve as a benchmark for future studies designed to improve outcomes for adults with medulloblastoma.
BACKGROUND AND PURPOSE: The optimal treatment for adults with newly diagnosed medulloblastoma (MB) has not been defined. We report a large series of cases from the Rare Cancer Network. MATERIAL AND METHODS: Thirteen institutions enrolled 206 MBpatients who underwent postoperative radiotherapy (RT) between 1976 and 2014. Log-rank univariate and Cox-modeled multivariate analyses were used to analyze data collected. RESULTS: Median patient age was 29 years; follow-up was 31 months. All patients had the tumor resected; surgery was complete in 140 (68%) patients. Postoperative RT was given in 202 (98%) patients, and 94% received craniospinal irradiation (CSI) and, usually, a posterior fossa boost. Ninety-eight (48%) patients had chemotherapy, mostly cisplatin and vincristine-based. The 10-year local control, overall survival, and disease-free survival rates were 46%, 51%, and 38%, respectively. In multivariate analyses, Karnofsky Performance Status (KPS) ≥80 and CSI were significant for disease-free and overall survival (P ≤ .04 for all); receiving chemotherapy and KPS ≥80 correlated with better local-control rates. CONCLUSIONS:Patients with high KPS who received CSI had better rates of disease-free and overall survival. Chemotherapy was associated with better local control. These results may serve as a benchmark for future studies designed to improve outcomes for adults with medulloblastoma.
Authors: Aleksandra Napieralska; Iwona Brąclik; Michał Radwan; Marek Mandera; Sławomir Blamek Journal: Childs Nerv Syst Date: 2018-12-04 Impact factor: 1.475
Authors: Nazanin K Majd; Maximilan Mastall; Heather Lin; Seyede Shiva Dibaj; Kenneth R Hess; Ying Yuan; Manuela Martin-Bejarano Garcia; Gregory N Fuller; Kristin D Alfaro; Maria K Gule-Monroe; Jason T Huse; Soumen Khatua; Ganesh Rao; David I Sandberg; Jeffrey S Wefel; Debra N Yeboa; Arnold C Paulino; Susan L McGovern; Wafik Zaky; Anita Mahajan; Dima Suki; Shiao-Pei Weathers; Rebecca A Harriso; John F De Groo; Vinay K Puduvalli; Marta Penas-Prado Journal: Neurooncol Adv Date: 2021-06-22
Authors: Mary Jane Lim-Fat; Maria Macdonald; Sarah Lapointe; Seth Andrew Climans; Chantel Cacciotti; Manik Chahal; Sebastien Perreault; Derek S Tsang; Andrew Gao; Stephen Yip; Julia Keith; Julie Bennett; Vijay Ramaswamy; Jay Detsky; Uri Tabori; Sunit Das; Cynthia Hawkins Journal: Front Oncol Date: 2022-09-23 Impact factor: 5.738